Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Boston, MA
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Berkley, MI
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Berkley, MI
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Camden, NJ
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Camden, NJ
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
East Orange, NJ
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
East Orange, NJ
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Newark, NJ
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Bronx, NY
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Durham, NC
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Huntersville, NC
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Huntersville, NC
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Winston Salem, NC
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Winston Salem, NC
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Cleveland, OH
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Portland, OR
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Philadelphia, PA
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Columbia, SC
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Austin, TX
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Dallas, TX
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Galveston, TX
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Galveston, TX
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Houston, TX
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Longview, TX
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Longview, TX
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Hampton, VA
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Hampton, VA
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Seattle, WA
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Milwaukee, WI
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
mi
from
Buenos Aires,
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
mi
from
Buenos Aires,
Click here to add this to my saved trials
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency (XSCID): A Phase 2 Study Assessing Safety and Clinical Response to Treatment With Insulin-like Growth Factor-1 (IGF-1)
Status: Enrolling
Updated:  7/2/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency (XSCID): A Phase 2 Study Assessing Safety and Clinical Response to Treatment With Insulin-like Growth Factor-1 (IGF-1)
Status: Enrolling
Updated: 7/2/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Drug Drug Interaction of BI 201335 and Tenofovir
Effect of Multiple Dosing With 240 mg BID BI 201335 on the Steady State Pharmacokinetics of 300mg QD Tenofovir and Effect of Multiple Dosing With 300mg QD Tenofovir on Steady State BI 201335 Pharmacokinetics in Healthy Male and Female Volunteers
Status: Enrolling
Updated:  7/3/2015
1218.74.01050 Boehringer Ingelheim Investigational Site
mi
from
Buffalo, NY
Drug Drug Interaction of BI 201335 and Tenofovir
Effect of Multiple Dosing With 240 mg BID BI 201335 on the Steady State Pharmacokinetics of 300mg QD Tenofovir and Effect of Multiple Dosing With 300mg QD Tenofovir on Steady State BI 201335 Pharmacokinetics in Healthy Male and Female Volunteers
Status: Enrolling
Updated: 7/3/2015
1218.74.01050 Boehringer Ingelheim Investigational Site
mi
from
Buffalo, NY
Click here to add this to my saved trials
Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women
Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women
Status: Enrolling
Updated:  7/8/2015
Grady Infectious Diseases Program
mi
from
Atlanta, GA
Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women
Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women
Status: Enrolling
Updated: 7/8/2015
Grady Infectious Diseases Program
mi
from
Atlanta, GA
Click here to add this to my saved trials
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
An Open Label, On-Treatment Trial to Assess the Effect of HIV-1 Coinfection on Therapeutic Responses Using Boceprevir, Peg-Interferon-alfa-2b and Ribavirin in HCV Genotype 1, IFN Treatment-Naive Subjects With or Without HIV-1
Status: Enrolling
Updated:  7/9/2015
Unity Health Care, Inc./DC General
mi
from
Washington, DC,
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
An Open Label, On-Treatment Trial to Assess the Effect of HIV-1 Coinfection on Therapeutic Responses Using Boceprevir, Peg-Interferon-alfa-2b and Ribavirin in HCV Genotype 1, IFN Treatment-Naive Subjects With or Without HIV-1
Status: Enrolling
Updated: 7/9/2015
Unity Health Care, Inc./DC General
mi
from
Washington, DC,
Click here to add this to my saved trials
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
An Open Label, On-Treatment Trial to Assess the Effect of HIV-1 Coinfection on Therapeutic Responses Using Boceprevir, Peg-Interferon-alfa-2b and Ribavirin in HCV Genotype 1, IFN Treatment-Naive Subjects With or Without HIV-1
Status: Enrolling
Updated:  7/9/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
An Open Label, On-Treatment Trial to Assess the Effect of HIV-1 Coinfection on Therapeutic Responses Using Boceprevir, Peg-Interferon-alfa-2b and Ribavirin in HCV Genotype 1, IFN Treatment-Naive Subjects With or Without HIV-1
Status: Enrolling
Updated: 7/9/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir
A Phase 1, Single-center, Randomized, Open-label, Crossover Study to Assess the Relative Bioavailability of Phase III Tablet Formulation Candidates in Healthy Adult Subjects
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Overland Park, KA
Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir
A Phase 1, Single-center, Randomized, Open-label, Crossover Study to Assess the Relative Bioavailability of Phase III Tablet Formulation Candidates in Healthy Adult Subjects
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects
A Pilot Study to Assess Virologic Suppression and Immune Recovery With Raltegravir and Lopinavir/Ritonavir and Raltegravir and Emtricitabine/Tenofovir in HIV-1 Infected Treatment-naïve Subjects
Status: Enrolling
Updated:  7/11/2015
University of Miami AIDS Clinical Research Unit
mi
from
Miami, FL
Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects
A Pilot Study to Assess Virologic Suppression and Immune Recovery With Raltegravir and Lopinavir/Ritonavir and Raltegravir and Emtricitabine/Tenofovir in HIV-1 Infected Treatment-naïve Subjects
Status: Enrolling
Updated: 7/11/2015
University of Miami AIDS Clinical Research Unit
mi
from
Miami, FL
Click here to add this to my saved trials
Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
Pilot Study of Raltegravir/Tenofovir/Emtricitabine Versus Efavirenz/Tenofovir/Emtricitabine for Adults With Acute HIV-1 Infection: Exploring the Role of Integrase Inhibition in Early HIV Pathogenesis
Status: Enrolling
Updated:  7/11/2015
UAB 1917 Clinic
mi
from
Birmingham, AL
Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
Pilot Study of Raltegravir/Tenofovir/Emtricitabine Versus Efavirenz/Tenofovir/Emtricitabine for Adults With Acute HIV-1 Infection: Exploring the Role of Integrase Inhibition in Early HIV Pathogenesis
Status: Enrolling
Updated: 7/11/2015
UAB 1917 Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders
Status: Enrolling
Updated:  7/14/2015
RAND
mi
from
Santa Monica, CA
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders
Status: Enrolling
Updated: 7/14/2015
RAND
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders
Status: Enrolling
Updated:  7/14/2015
Infectious Diseases Institute
mi
from
Kampala,
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders
Status: Enrolling
Updated: 7/14/2015
Infectious Diseases Institute
mi
from
Kampala,
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from
Long Beach, CA
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from
Palm Springs, CA
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from
San Francisco, CA
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from
Norwalk, CT
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from
Norwalk, CT
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from
Washington,
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from
Orlando, FL
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from
New York, NY
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from
New York, NY
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from
Austin, TX
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from
Dallas, TX
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Stanford Universities: The Stanford HIV Aging Cohort
The Stanford HIV Aging Cohort (SHAC)
Status: Enrolling
Updated:  7/15/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Stanford Universities: The Stanford HIV Aging Cohort
The Stanford HIV Aging Cohort (SHAC)
Status: Enrolling
Updated: 7/15/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Clinical Evaluation of the Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Status: Enrolling
Updated:  7/20/2015
Fenway Community Health
mi
from
Boston, MA
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Clinical Evaluation of the Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Status: Enrolling
Updated: 7/20/2015
Fenway Community Health
mi
from
Boston, MA
Click here to add this to my saved trials
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Clinical Evaluation of the Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Status: Enrolling
Updated:  7/20/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Clinical Evaluation of the Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Status: Enrolling
Updated: 7/20/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Clinical Evaluation of the Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Status: Enrolling
Updated:  7/20/2015
Miriam Hospital
mi
from
Providence, RI
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Clinical Evaluation of the Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Status: Enrolling
Updated: 7/20/2015
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Effectiveness of Structured Ecosystems Therapy for Reducing HIV Risk Behaviors and Improving Treatment Adherence in HIV Infected Men Released From Prison
Ecosystems Therapy for Men Reintegrating Into Their Family
Status: Enrolling
Updated:  7/22/2015
University of California at San Francisco
mi
from
San Francisco, CA
Effectiveness of Structured Ecosystems Therapy for Reducing HIV Risk Behaviors and Improving Treatment Adherence in HIV Infected Men Released From Prison
Ecosystems Therapy for Men Reintegrating Into Their Family
Status: Enrolling
Updated: 7/22/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
Phase IIIb/IV Randomized, Controlled Study Evaluating an Intensification Treatment Strategy of Adding Enfuvirtide (ENF) to an Oral Highly Active AntiRetroviral Therapy (HAART) in Treatment Experienced Patients
Status: Enrolling
Updated:  7/22/2015
Clinical Research Facility
mi
from
Cleveland, OH
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
Phase IIIb/IV Randomized, Controlled Study Evaluating an Intensification Treatment Strategy of Adding Enfuvirtide (ENF) to an Oral Highly Active AntiRetroviral Therapy (HAART) in Treatment Experienced Patients
Status: Enrolling
Updated: 7/22/2015
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
Phase IIIb/IV Randomized, Controlled Study Evaluating an Intensification Treatment Strategy of Adding Enfuvirtide (ENF) to an Oral Highly Active AntiRetroviral Therapy (HAART) in Treatment Experienced Patients
Status: Enrolling
Updated:  7/22/2015
Clinical Research Facility
mi
from
Austin, TX
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
Phase IIIb/IV Randomized, Controlled Study Evaluating an Intensification Treatment Strategy of Adding Enfuvirtide (ENF) to an Oral Highly Active AntiRetroviral Therapy (HAART) in Treatment Experienced Patients
Status: Enrolling
Updated: 7/22/2015
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
Phase IIIb/IV Randomized, Controlled Study Evaluating an Intensification Treatment Strategy of Adding Enfuvirtide (ENF) to an Oral Highly Active AntiRetroviral Therapy (HAART) in Treatment Experienced Patients
Status: Enrolling
Updated:  7/22/2015
Clinical Research Facility
mi
from
Dallas, TX
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
Phase IIIb/IV Randomized, Controlled Study Evaluating an Intensification Treatment Strategy of Adding Enfuvirtide (ENF) to an Oral Highly Active AntiRetroviral Therapy (HAART) in Treatment Experienced Patients
Status: Enrolling
Updated: 7/22/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials